
    
      Primary Objective:

        -  To assess tolerability/safety (incidence of adverse events 21-28 days following
           vaccination) of the study drug.

      Secondary Objectives:

        -  To assess the efficacy (immunogenicity) of the study drug by serology testing of blood
           samples taken at Day 21-28 after immunization in groups and age groups.

        -  To assess long term (180-210 days following vaccination) tolerability/safety (incidence
           of adverse events) of the study drug.
    
  